You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
DR?1-MOG as a Next-Generation Immunotherapy for Methamphetamine Use Disorder
SBC: VIROGENOMICS BIODEVELOPMENT INC Topic: R41Methamphetamine use disorder is associated with damage to regions of the brain that control cognitive and psychiatric functionOne third to one half of adults with methamphetamine use disorder experience cognitive impairments and other psychiatric symptoms that significantly impact treatment outcomesincreased relapse and lower treatment retention ratesMounting evidence demonstrates how immune facto ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Multimodality image-based assessment system for traumatic brain injury
SBC: KITWARE INC Topic: NINDSDESCRIPTION (provided by applicant): Nearly 1.7 million Americans suffer traumatic brain injury (TBI) annually, which constitutes an important and significant US medical health concern. Although neuroimaging plays an important role in pathology localization and surgical planning, TBI clinical care does not currently take full advantage of neuroimaging computational technology. We propose to develo ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Integration of Immunochemical, Genomic and Transcriptomic Analyses of Human Skin
SBC: INTEGRATED TISSUE DYNAMICS LLC Topic: NINDSDESCRIPTION (provided by applicant): Wide varieties of peripheral neuropathies accompanied by severe chronic pain are among the most common and debilitating human afflictions. Existing treatments have little long term benefits and often have severe side effects. Increasing evidence indicates that pathologies in the structure and chemistry of the skin and its innervation are likely contributors to ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
The anti-tumorigenic and anti-metastatic potential of Eya phosphatase inhibitors
SBC: SIXONE SOLUTIONS, LLC Topic: NCIDESCRIPTION (provided by applicant): Breast cancer is expected to cause 39,510 deaths of American women in 2012 and 450,000 deaths globally. Once breast cancer has spread, it is essentially incurable. A critical barrier to treating advanced breast cancer is the lack of cancer-specific drugs that are effective in a large percentage of cancer patients and have low toxicity. Sixone Solutions, LLC pro ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Clinical Translation of an Anti-Metastatic Antibody for Breast Cancer Therapy
SBC: FOR-ROBIN, INC. Topic: NCIDESCRIPTION (provided by applicant): This proposal aims to develop a novel, highly-specific targeted therapy for treatment of breast cancer. The long-term objective is to convert the proprietary intellectual property, the mouse monoclonal antibody (McAb)JAA-F11, which targets the pancarcinoma Thomsen-Friedenreich antigen (TF-Ag) to a humanized form for use as an adjunct with conventional therapy ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Science Take-Out Kits for Improving Environmental Health Literacy on Vaping
SBC: Science Take-Out, LLC Topic: RABSTRACT This supplement project will expand on our current STTR Phase I project in which we partnered with University of Rochesterandapos;s Environmental Health Sciences Center to develop three Science Take-Out vaping education kits. Our vaping education kits involve students in using hands-on activities and real-life scenarios to investigate the harmful effects of chemicals used in e-cigarette f ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Direct-read monitor for airborne viral pathogens
SBC: AEROSOL DEVICES INC Topic: NIAIDAerosolized pathogenssuch as Influenza virusescan spread rapidly and silently throughout a populationcausing severe outbreaks that can be difficult to controlEarly detection of these airborne pathogens is key to controlling outbreaksespecially among vulnerable populations such as in hospitalstreatment centers or nursing homesYet available methods are neither rapidnor portableCurrent methods rely h ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Topical Nanoparticles for CNV
SBC: NANOTRANS TECHNOLOGIES, INC. Topic: NEIDESCRIPTION (provided by applicant): Age Related Macular Degeneration (AMD) is the leading cause of blindness in adults over 50 years. Choroidal neovascularization (CNV), the pathologic creation of new blood vessels in the choroid layer of the eye, is a principal cause of blindness due to AMD. Current therapeutic management of AMD is far from optimal and requires repeated injections in the vitreou ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Live-Cell Fluorescence Lifetime FRET Assays for HTS
SBC: Fluorescence Innovations, Inc. Topic: NIDADESCRIPTION (provided by applicant): This project will establish proof-of-concept for a powerful and versatile implementation of live-cell assays in a true high-throughput screening (HTS) format for small-molecule drug discovery. The technological basis isfluorescence lifetime (FLT) readout of FRET between fluorescent fusion proteins. Lifetime measurement is needed in HTS to overcome the low preci ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Fluorescence Image-Guided Near Infrared (NIR) Photodynamic Therapy (PDT) Agent
SBC: PHOTOLITEC LLC Topic: NCIDESCRIPTION (provided by applicant): Photolitec's patented technology is focused on developing improved agents for tumor- imaging, image-guided surgery and/or photodynamic therapy (PDT). The proposed STTR proposal includes fluorescence-image guided PDT, aSee and Treat approach. The fluorescence imaging compound with long wavelength absorption near 800 nm should be extremely useful for image ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health